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Abstract
Background: Neurocysticercosis (NC) is one of the most frequent parasitic diseases of the central nervous system.
Cysticidal drugs, albendazole and praziquantel, are generally effective when parasites localize in the parenchyma. In
contrast, parasites lodged in the subarachnoid basal cisterns are less responsive to treatment.
Case Presentation: The clinical and radiological pictures of six Mexican patients non-respondent to cysticidal
treatment are presented.
Conclusions: The possible factors involved in the cysticidal non-response are discussed and hints are provided of
potentially useful changes to therapeutic protocols.
Background
Taenia solium is a parasite which larvae (cysticercus)
may localize in the central nervous system of humans
causing neurocysticercosis (NC). Most NC cases occur
with little or no neurological symptoms but others may
present a variety of non-specific mild clinical symptoms
(headache, partial seizures) or severe neurological syn-
dromes with intracraneal hypertension and generalized
seizures [1].
The introduction of cysticidal drugs, albendazole
(ABZ) and praziquantel (PZQ), for the treatment of NC
have dramatically improved its prognosis [2]. In Mexico,
ABZ is becoming the drug of choice due to its low costs
and availability. Parasite localization is one of the main
factors involved in the success of the treatment. When
cysticerci are lodged in the parenchyma, the use of these
drugs allows generally a prompt radiological and clinical
improvement in most of the patients although only a
modest effect is reported in some cases [3,4]. When the
parasites are located in the subarachnoid basal cisterns
(SA-NC), the prognosis is more uncertain. Several case
series have reported the effectiveness of these drugs in
SA-NC treatment [5-7]. However, in our experience and
that of others [4], it is a frequent finding that the para-
sites persist after treatment, even when a high dose of
ABZ has been used [8].
In this report, six cases NC-SA patients who are non-
respondent to conventional pharmacological treatment
and a brief review of literature are described.
Case Presentation
Patient A (Figure 1, A0 to 1A3). A 46-year-old man with
one year history of increasing incapacitating frontal
headache. Upon admission, bilateral papilledema and
upward gaze paralysis were shown. Multiple vesicular
cysticerci located in opto-chiasmatic and perimensence-
phalic cisterns as well as basal meningeal enhancement
were observed by magnetic resonance imaging (MRI).
Increased cellularity (89 cells/mm3) and anti-cysticercal
antibodies (Abs) determined by ELISA were detected in
the cerebrospinal fluid (CSF). During one year, the
patient received two cycles of ABZ (30 mg/kg/day) and
one course of PZQ (50 mg/kg), for eight days, associated
to corticosteroids. In the ninth month, he required a
ventriculoperitoneal shunt (VPS) due to hydrocephaly.
In all of MRIs, which were performed four months after
each treatment cycle, most of the vesicular parasites
persisted.
Patient B (Figure 1, B0 to 1B3). A 60 year old man
with chronic headache. Nine months before hospital
admission, headache frequency increased and lower limb
motor dysfunction appeared. Neurological examination
revealed only papilledema. On MRI, vesicular subarach-
noidal NC in posterior fossa was observed. CSF analysis
showed an inflammatory profile with abundant
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lymphocytes and eosinophils. During the year following
the diagnosis, he received two courses of ABZ at 30 mg/
kg/day during 8 days and one course of ABZ at the
same dose, associated with PZQ at 50 mg/kg plus corti-
costeroids. However, radiological evidence of vesicular
parasites was still observed and CSF inflammatory pro-
file and clinical complaints persisted.
Patient C (Figure 1, C0 to 1C5). A 29-year old man
with new onset generalized seizures. CT scan showed
vesicular NC and he received ABZ plus steroids in the
United States of America. Post treatment, progressive
motor dysphasia, right sided weakness and intracranial
hypertension signs appeared. The patient returned to
Mexico. MRI showed vesicular racemose cysticercosis
on left Sylvian fissure with displacement of midline
anatomical structures. A second ABZ cycle was adminis-
tered and although the racemose cyst evinced a substan-
tial reduction, other SA vesicular parasites appeared.
During two years this patient received four other
courses of ABZ (30 mg/kg/day during eight days) and
two combined courses of ABZ and PZQ. These treat-
ments were delivered at the same doses as with the
other patients and showed no evidence of parasite
eradication.
Patient D (Figure 1, D4 to 1D7). A 65-year-old woman
with vomiting, papilledema, gait disturbances, and urin-
ary incontinency. The patient had a 6-year history of
chronic headache. On admission, CT scan showed mul-
tiple vesicular parasites in the Sylvian fissure with mass
effect. A surgical removal of parasites located in the
Figure 1 MRI of patients. Letters correspond to each of the patients and numbers corresponds to the moment of the MRI in relation to the
number of cysticidal cycles administered (0: basal MRI, 1: after the first cycle, etc.). A0 (MRI T2 FLAIR): vesicular cysticerci in basal cisterns.
Decrease (A2, MRI CE, T1) and increase (A3, MRI T2 FLAIR) in parasites. B0 (MRI CE T1): Vesicular parasites in the pontocerebellar angle. B1:
Increase of parasite. B3: Persistence of parasite. C0 (MRI T2): Cysticercus in the Sylvian and basal cisterns. C1 (MRI T2, FLAIR): Decrease in Sylvian
and persistence of basal cisterns parasites. C2 (MRI T2): Increase of lamina terminalis and basal cisterns parasites. C3 (MRI T2): Decrease of basal
cisterns parasites. C4 (MRI CE T1): Increase of basal cisterns parasites and appearance of new ones. C5 (MRI FLAIR): Persistence of parasites. D4
(MRI T2): Parasites in the right pontocerebellar angle and in the lamina terminalis cisterns. D5 (MRI T2): Decrease of parasite volume. D6 (MRI T2):
Increase of the lamina terminal cistern vesicles. D7 (MRI FLAIR, T2): Persistence of vesicles.
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right Sylvian fissure and opto-chiasmatic cistern was
performed. Three months after surgical procedure, a CT
scan showed persistence of subarachnoid vesicular para-
sites in the chiasma and pontocerebellar cistern. CSF
analysis revealed an inflammatory profile (20 cells/mm3)
with presence of anti-cysticercal Abs. During four years,
patient completed seven courses of ABZ (30 mg/kg/day
during 8 days) associated to corticosteroids without
complete clinical and radiological improvement.
Patient E (Figure 2, E3 to 2E7). A 40-year old man
with a one-year-history of increasing headache, in fre-
quency and intensity, associated with sporadic vomit-
ing and generalized seizures. Papilledema and left
slight motor weakness were observed on neurological
examinations. A CT scan revealed a vesicular racemose
cysticercus on the right Sylvian fissure, upon which
surgical excision of parasites was performed. Diagnosis
of vesicular cysticerci was confirmed by histopathology.
Post-treatment, the patient showed clinical improve-
ment, but six months later, motor deficit reappeared.
MRI showed recurrence of parasites at the same loca-
tion and CSF was inflammatory. During the five years
following the first surgery, the parasites did not disap-
pear in spite of the administration of seven courses of
ABZ and one combined course of ABZ and PZQ with
corticosteroids. Clinically, the patient presents memory
loss and corticosteroids side-effects as hyperglycemia
and myopathy.
Patient F (Figure 2, F2 to 2F6). A 26-year old man
with new onset partial motor epilepsy. His CT scan
showed perimesencephalic vesicular parasites and CSF
was inflammatory (75 cells/mm3) with specific anticysti-
cercal Abs. During the following five years, the patient
received 7 courses of ABZ (30 mg/kg/day during eight
days with corticosteroids) and he required the place-
ment of a VPS for hydrocephalus during the fourth
year. In spite of the received treatment, vesicular para-
sites persisted on the last MRI, and CSF was still
inflammatory.
Conclusion
This article reports six SA-NC patients in whom para-
sites relapsed despite repetitive administration of cysti-
cidal treatment. Other non-responsive NC cases have
been previously published (Table 1, [9-12]) but includ-
ing patients that differ in the clinical picture, the para-
site localization and cysticidal doses used. Even though
the causes of the parasite’s persistence, despite the
ABZ treatment, are still unknown, multiple host and
parasite factors may be involved. The possibility that
Figure 2 MRI of patients. E3 (MRI T2, T1): Parasites in Sylvian, basal and lamina terminalis cisterns. E4 and E5 (MRI T2, FLAIR): Persistence of
some of the parasites. E6 (MRI simple, CE T1): Persistence of lamina terminalis parasites and appearance of new ones. E7 (MRI FLAIR, T2):
Persistence of parasites. F2 (MRI T1): Parasites in the crural and ambient cisterns. F3 (MRI T1), F4, F5 and F6 (MRI T2): Persistence of ambient
cistern parasites.
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the cysticidal drugs differentially affect the parasites
according to their developmental stage (radiologically
not- definable) could be a factor involved in the non-
response observed. It is also possible that the lesser
penetration of ABZ in the subarachnoidal space could
participate in the SA-NC resistance. Another factor
involved in this phenomenon could be related to the
variability in plasma and CSF ABZ sulphoxide levels
among patients due to individual differences in bioa-
vailability [2]. The high levels of corticosteroids used
to prevent complications due to severe CSF inflamma-
tion may also turn-off key immunological components
crucial for the parasite destruction. Finally, although
resistance of cysticerci to ABZ in humans has never
been reported, it may occur as it has been observed in
other related parasites [13-15].
Whatever are the reasons, this scenario clearly points
out to the relevance of developing new therapeutic stra-
tegies. One approach could be the elaboration of new
albendazole formulations in order to improve its bioa-
vailability and therapeutic efficacy [16]. Another
approach is the search of new pharmacological alterna-
tives as ivermectine, which seems to destroy cysticerci
in patients resistant to cysticercidal drugs [11]. Nitazox-
anide and tizoxanide combined with ABZ have also
shown promising results albeit in vitro and using
another related cestode [17].
Finally, although these non-respondent cases are not the
most frequent, their severity should encourage controlled
studies to evaluate new forms of medical intervention and
management. In particular, fuller understanding of the key
elements that participate in controlling the inflammatory
response would greatly help in devising new, potent and
less harmful ways to prevent severe disease.
Consent
Written informed consent was obtained from the
patients for publication of these cases report and any
accompanying images. A copy of the written consents is
available for review by the Editor-in-Chief of this
journal.
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